| Literature DB >> 29966094 |
Carlos Roca1, Loreto Martinez-González1, Miguel Daniel-Mozo2, Javier Sastre1, Lourdes Infantes2, Alicia Mansilla3, Antonio Chaves-Sanjuan2, Juana María González-Rubio2, Carmen Gil1, F Javier Cañada1, Ana Martinez1, María José Sanchez-Barrena2, Nuria E Campillo1.
Abstract
Protein-protein interactions (PPIs) are known to play an essential role between the neuronal calcium sensor 1 (NCS-1) and the guanine exchange factor Ric8a to regulate synapse function, emerging as a druggable interface for synaptopathies such as the fragile X syndrome (FXS). Recently, the phenothiazine FD44 has been identified as an inhibitor of this PPI, decreasing the abnormally high synapse number and enhancing associative learning in a FXS animal model. Here, we have integrated advanced experimental and computational studies to obtain important structural insights into Drosophila NCS-1/FD44 recognition to understand the basis of its affinity and specificity and generate improved PPI regulators. This has allowed the identification of a new small drug-like molecule, IGS-1.76, which efficiently inhibits the human NCS-1/Ric8a complex with improved binding potency. The crystal structure of the Drosophila NCS-1/IGS-1.76 complex demonstrates that the new inhibitor, although chemically different from FD44, shares the same mechanism of action and constitutes a new hit candidate for FXS.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29966094 DOI: 10.1021/acs.jmedchem.8b00088
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446